Muzahir Saima, Jeraj Robert, Liu Glenn, Hall Lance T, Rio Alejandro Munoz Del, Perk Timothy, Jaskowiak Christine, Perlman Scott B
Department of Radiology, Division of Nuclear Medicine, University of Wisconsin Madison Madison, WI, USA.
Department of Medical Physics, University of Wisconsin Madison Madison, WI, USA.
Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):162-8. eCollection 2015.
Fluorine 18 Sodium Fluoride ((18)F-NaF) (sodium fluoride) PET/CT is a highly sensitive but is a non-specific method for identifying bone metastases. Qualitative scan interpretation using low dose CT for lesion localization is often complicated by the presence of co-existing degenerative joint disease (DJD). A semi-quantitative analysis might help in accurately differentiating benign from metastatic osseous lesions. The aim of the study was to evaluate the clinical utility of (18)F-NaF PET/CT in differentiating DJD from metastatic disease in the skeleton using a qualitative analysis as well as a semi-quantitative approach using the SUVmax and to determine if there is an upper limit of SUVmax value that can reliably differentiate metastases from DJD. Baseline (18)F-NaF PET/CT scans were performed for 17 castrate resistant prostate cancer patients (CRPC). A qualitative as well as semi-quantitative analysis using maximum standardized uptake value (SUVmax) based on body weight was performed for 65 metastatic and 56 DJD sites identified on the low dose CT scan acquired as a part of whole body PET/CT scan. The SUVmax range in DJD was 2.6-49.9 (mean: 6.2). The SUVmax range for metastatic lesions was 11.2-188 (mean: 160). The SUVmax value for metastatic as well as areas of DJD showed significant variation during treatment. Bone metastases showed statistically significantly higher SUVmax than DJD using a mixed effect regression model. ROC/AUC analysis was performed based on averaging the SUVs over all lesions in each subject. The AUC was found to be fairly high at 0.964 (95% CI: 0.75-0.996). The SUVmax over 50 always represented a bone metastasis and below 12 always represented a site of DJD. The results of our preliminary data show that semi-quantitative analysis is complementary to the qualitative analysis in accurately identifying DJD from metastatic disease. The cut-off SUVmax of 50 can help in differentiating DJD from bone metastases.
氟-18 氟化钠((18)F-NaF)正电子发射断层显像/X线计算机体层成像(PET/CT)是一种用于识别骨转移的高灵敏度但非特异性的方法。使用低剂量CT进行病变定位的定性扫描解读常常因并存的退行性关节病(DJD)而变得复杂。半定量分析可能有助于准确区分良性和转移性骨病变。本研究的目的是通过定性分析以及使用最大标准化摄取值(SUVmax)的半定量方法,评估(18)F-NaF PET/CT在鉴别骨骼中DJD与转移性疾病方面的临床效用,并确定是否存在能可靠区分转移灶与DJD的SUVmax值上限。对17例去势抵抗性前列腺癌(CRPC)患者进行了基线(18)F-NaF PET/CT扫描。对作为全身PET/CT扫描一部分所获取的低剂量CT扫描上识别出的65个转移灶部位和56个DJD部位,基于体重进行了定性以及使用最大标准化摄取值(SUVmax)的半定量分析。DJD的SUVmax范围为2.6 - 49.9(均值:6.2)。转移灶的SUVmax范围为11.2 - 188(均值:160)。转移灶以及DJD区域的SUVmax值在治疗期间显示出显著变化。使用混合效应回归模型,骨转移灶的SUVmax在统计学上显著高于DJD。基于对每个受试者所有病变的SUV进行平均,进行了ROC/AUC分析。发现AUC相当高,为0.964(95%置信区间:0.75 - 0.996)。SUVmax超过50总是代表骨转移,低于12总是代表DJD部位。我们初步数据的结果表明,半定量分析在准确鉴别转移性疾病与DJD方面是对定性分析的补充。SUVmax的截断值50有助于区分DJD与骨转移。